Success Stories: EB-1A Approved for Chemical Biology Researcher Advancing Small-Molecule Design and Molecular Imaging

Client’s Testimonial:

“Thank you for the prompt information! It has been a great pleasure working with you and your team at We Green. I truly appreciate the support and professionalism throughout the process.”

On August 1^st, 2025, we received another EB1A (Alien of Extraordinary Ability) approval for a Visiting Postdoctoral Fellow in the field of Chemical Biology (Approval Notice).

General Field: Chemical Biology

Position at the Time of Case Filing: Visiting Postdoctoral Fellow

Country of Origin: China

State of Residence at the Time of Filing: Maryland

Approval Notice Date: August 1^st, 2025

Processing Time: 1 month, 26 days (Premium Processing Requested)

Case Summary:

We are pleased to share the success story of an EB-1A petition approval granted to a visiting postdoctoral fellow whose pioneering work in small-molecule design, protein engineering, and bioluminescent imaging has produced transformative tools for probing cellular processes and advancing therapeutic discovery.

Research Focus and Contributions

The petition highlighted the client’s innovative research program, which includes:

Engineering metabolic chemical reporters to map post-translational histone modifications in living cells
Developing red-shifted bioluminescent sensors for functional brain imaging and high-sensitivity bioassays
Creating novel coelenterazine-based probes to enable deep-tissue tumor imaging with enhanced resolution

Research Impact and Metrics

To demonstrate extraordinary ability, the petition assembled key quantitative metrics:

12 peer-reviewed journal articles documenting first-in-field structural and imaging advances
455 total citations, placing the researcher among the top 1 percent most-cited authors in bioluminescence and chemical biology
At least 65 invited manuscript reviews for high-impact journals, confirming recognition as a field authority

Here is an anonymized excerpt from a recommendation letter that underscores the practical impact of his work:

“Despite the high costs and limited accessibility of advanced imaging modalities like immuno-PET, the [client’s] work on novel bioluminescence pairs and an immunobioluminescence platform offers a more affordable, reliable alternative, democratizing access to cutting-edge imaging for researchers and clinicians alike.”

Demonstrating Extraordinary Ability

The petition provided evidence of independent adoption of the client’s imaging tools by global research teams and extensive peer review and editorial board service for leading journals. A final merits determination aggregated these criteria and confirmed that the client ranks among the very small percentage at the pinnacle of chemical biology.

Well Positioned for Continued Innovation

The petition documented the client’s advanced training (Ph.D. in chemical biology), extensive postdoctoral and staff-scientist experience, and leadership of multidisciplinary collaborations to translate bespoke molecular tools into preclinical and clinical applications, establishing a strong foundation for future breakthroughs in therapeutic development.

Approval and Outcome

Filed June 6, 2025, under direct premium processing, and approved August 1, 2025, in just 1 month and 26 days, this EB-1A approval underscores the United States’ commitment to retaining exceptional talent in critical scientific fields. NAILG is proud to have guided this client through a seamless EB-1A process and looks forward to supporting ongoing contributions to global health innovation.

North America Immigration Law Group (Chen Immigration Law Associates) is a U.S. immigration law firm dedicated to representing corporations, research institutions, and individuals from all 50 U.S. states regarding I-140 immigration petitions. We specialize in employment-based immigration petition and have a proven record of high success rate for the categories of: EB2-NIW (National Interest Waiver), EB1-A (Alien of Extraordinary Ability), EB1-B (Outstanding Researcher/Professor) and O-1 (Alien of Extraordinary Ability).

Our Ten Thousand I-140 Approvals Provide Unprecedented Insight into the USCIS Adjudication Trend

With more than 58,000 EB-1A, EB-1B, EB-2 NIW and O-1 cases approved, we have first hand information on the manner in which the USCIS adjudicate I-140 cases. As the USCIS has constantly changed its adjudication standards for the EB-1A, EB-1B and EB-2 NIW categories, our firm's huge database of successful cases gives you unprecedented insight to USCIS adjudication trends. We carefully analyze the data for all of our cases and apply the results of our analyses toward giving our clients up-to-date advice and adapting our strategies such that we remain on par with the ever-shifting landscape of immigration law in the U.S. With us, you will always have access to important updates, strategies, and information so that you can make the most informed decisions about your case.

We Have Helped Hundreds and Thousands of Clients with Credentials and Backgrounds Similar to Yours

With our exceedingly large number of successful petitions, no matter what credentials you have, no matter your background and field of expertise, no matter your visa status or nationality, chances are we have helped hundreds or even thousands of clients just like you. Our clients are usually impressed with how well we understand their research and work. Our insight and understanding stems from the fact that we have handled many cases with elements similar to yours already, and this helps us devise the best strategies for each individual petition.

Vast Majority of Clients Came to Us Because of Referrals

For years, our firm has attracted new clients based solely on word of mouth, recommendations, and the positive collaboration experiences shared with them by their friends and family. We take pride in our reputation and work hard to ensure that we provide a green card application experience that our clients are happy to share with their friends and colleagues. That is how our cumulative total of approved cases grew from 600 in 2013 to over 58,000 in 2025.